Investor Presentation First Nine Months of 2023
144
Investor presentation
First nine months of 2023
Resource allocation in Novo Nordisk is guided by investing in
future growth while delivering attractive shareholder returns
Corporate strategy guides resource allocation
Diabetes
Strengthen leadership by
offering innovative
medicines and driving
patient outcomes
Rare Disease
Secure a leading position
by leveraging full portfolio
and expanding into
adjacent areas
Novo
Nordisk
Way
Driving change
to defeat serious
chronic diseases
Sustainable
business
Obesity
Strengthen leadership
through market
development and by offering
innovative medicines and
driving patient outcomes
Other Serious
Chronic Diseases
Establish presence by
building competitive pipeline
and scientific leadership
Expected primary sales growth drivers towards 2030
Waves of growth
GLP-1
Diabetes
Obesity
care
OSCD
Novo NordiskⓇ
ILLUSTRATIVE
Research technology
Rare disease
platforms
Focus on driving sustained sales growth
•
Commercial investments in growth markets and products
•
R&D investments in future growth assets
R&D: Research and Development; OSCD: Other serious chronic diseases
2020
2025
2030View entire presentation